Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Pipeline Therapeutics to Participate in the 19th Annual Needham Virtual Healthcare Conference


Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that the company will participate in the 19th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking place April 14-15.

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor (GSI) to treat mild-to-moderate sensorineural hearing loss (SNHL) associated with cochlear synaptopathy. The company also has a portfolio of programs, including PIPE-307, focused on remyelination and axonal repair, to address a range of neurological disorders, including multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.


These press releases may also interest you

at 17:44
On Tuesday, May 7, 2024, The Center for Discovery® (TCFD, The Center) honored Edward C. Sweeney, TCFD Board Chair, at the 24th annual Evening of Discovery Gala. The Gala was hosted by Mo Rocca, CBS Sunday Morning Correspondent, Humorist, and Creator...

at 17:30
PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibodyThe clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the...

at 17:30
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association...

at 17:19
Long-time Madison podiatrist Colin Graney, DPM, has announced both the closing of his practice and that the Board Certified and Fellowship Trained physicians at Orthopedic & Spine Centers of Wisconsin will provide continuing care for his patients....

at 17:03
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary...

at 16:42
Accelerate Diagnostics, Inc. today announced financial preliminary results for the first quarter ended March 31, 2024. "During the...



News published on and distributed by: